Mario Germano Giuliani Sells 232,185 Shares of Royalty Pharma plc (NASDAQ:RPRX) Stock

Royalty Pharma plc (NASDAQ:RPRXGet Rating) Director Mario Germano Giuliani sold 232,185 shares of Royalty Pharma stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $41.50, for a total transaction of $9,635,677.50. Following the sale, the director now owns 22,657,815 shares in the company, valued at approximately $940,299,322.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mario Germano Giuliani also recently made the following trade(s):

  • On Friday, September 16th, Mario Germano Giuliani sold 154,986 shares of Royalty Pharma stock. The shares were sold at an average price of $41.72, for a total transaction of $6,466,015.92.
  • On Wednesday, September 7th, Mario Germano Giuliani sold 261,881 shares of Royalty Pharma stock. The stock was sold at an average price of $42.66, for a total transaction of $11,171,843.46.
  • On Thursday, August 25th, Mario Germano Giuliani sold 500 shares of Royalty Pharma stock. The stock was sold at an average price of $44.00, for a total transaction of $22,000.00.

Royalty Pharma Stock Performance

Royalty Pharma stock opened at $40.70 on Thursday. The company has a market cap of $24.71 billion, a PE ratio of 52.86, a P/E/G ratio of 1.11 and a beta of 0.30. The company has a fifty day moving average price of $43.00 and a two-hundred day moving average price of $41.49. The company has a debt-to-equity ratio of 0.68, a current ratio of 19.22 and a quick ratio of 19.22. Royalty Pharma plc has a 12 month low of $34.86 and a 12 month high of $44.75.

Royalty Pharma Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, September 15th. Stockholders of record on Friday, August 19th were issued a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a dividend yield of 1.87%. The ex-dividend date of this dividend was Thursday, August 18th. Royalty Pharma’s dividend payout ratio (DPR) is 98.70%.

Hedge Funds Weigh In On Royalty Pharma

Several hedge funds and other institutional investors have recently modified their holdings of the company. Signaturefd LLC lifted its holdings in Royalty Pharma by 53.9% in the first quarter. Signaturefd LLC now owns 688 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 241 shares during the period. Aurora Investment Counsel lifted its stake in shares of Royalty Pharma by 0.9% in the 1st quarter. Aurora Investment Counsel now owns 29,939 shares of the biopharmaceutical company’s stock valued at $1,166,000 after purchasing an additional 257 shares during the last quarter. Humankind Investments LLC boosted its stake in shares of Royalty Pharma by 4.6% during the 4th quarter. Humankind Investments LLC now owns 6,122 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 269 shares in the last quarter. Gulf International Bank UK Ltd grew its holdings in Royalty Pharma by 0.5% during the first quarter. Gulf International Bank UK Ltd now owns 57,580 shares of the biopharmaceutical company’s stock valued at $2,243,000 after purchasing an additional 300 shares during the last quarter. Finally, Advisor Group Holdings Inc. raised its holdings in Royalty Pharma by 9.4% in the 1st quarter. Advisor Group Holdings Inc. now owns 4,265 shares of the biopharmaceutical company’s stock worth $151,000 after acquiring an additional 366 shares during the period. Institutional investors and hedge funds own 54.94% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on RPRX. Citigroup lifted their price target on shares of Royalty Pharma from $50.00 to $60.00 in a research note on Thursday, July 28th. Tigress Financial lifted their price target on shares of Royalty Pharma from $52.00 to $57.00 and gave the stock a “buy” rating in a research note on Thursday, July 14th. UBS Group began coverage on shares of Royalty Pharma in a research note on Monday, June 13th. They issued a “buy” rating and a $47.00 price target for the company. Finally, Morgan Stanley lifted their price target on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a research note on Monday, August 8th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $53.43.

About Royalty Pharma

(Get Rating)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

Read More

Insider Buying and Selling by Quarter for Royalty Pharma (NASDAQ:RPRX)

Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.